Actuate Gets Nasdaq Bid-Price Notice, 180 Days to Reach $1.00
ACTU is trading near its 52-week low of $0.33 (1.5% above the low).
Summary
Actuate received a Nasdaq minimum bid price deficiency notice on October 28, 2026, giving it until April 26, 2027 to hold a $1.00 bid for 10 consecutive days — a second listing deficiency alongside the pending MVLS notice.
Key Events · Legal and Risk Events · ACTU
-
Nasdaq Bid-Price Deficiency Notice
On October 28, 2026 Nasdaq notified Actuate that its common stock closed below the $1.00 minimum bid price for 30 consecutive business days, breaching Listing Rule 5450(a)(1).
-
180-Day Cure Window to April 26, 2027
The company has until April 26, 2027 to close at $1.00 or above for a minimum of 10 consecutive business days; a second 180-day period requires transferring to the Nasdaq Capital Market and meeting its initial listing standards.
-
Second Listing Deficiency Already Pending
A separate July 15, 2026 notice for failing the minimum market value of listed securities requirement gives Actuate until January 11, 2027 to cure; the new bid-price notice does not extend that deadline.
-
Cure Likely Requires Reverse Split
At $0.3351 the stock sits about two-thirds below the $1.00 threshold, so regaining compliance would most likely require a reverse stock split, layered on the 30,985,900 shares and 15,492,950 warrants issued in the offering closed October 28, 2026.
Analysis · ACTU · Life Sciences
Actuate closed below $1.00 for 30 straight business days and now has until April 26, 2027 to get its bid back above $1.00 for at least 10 consecutive days. This is a second, separate listing deficiency stacked on the MVLS notice received July 15, 2026 (deadline January 11, 2027), so the company is fighting two Nasdaq fronts at once. The stock trades at $0.3351, roughly a third of the required bid, meaning a reverse split is the most plausible cure — and that would come on top of the 30,985,900 shares and 15,492,950 warrants just issued in the $11.0 million offering closed October 28. Failure to cure leads to delisting.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ACTU was trading at $0.34 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8M. The 52-week trading range was $0.33 to $7.90. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.